A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Royal Marsden NHS Foundation Trust
Centre Leon Berard
University of Michigan Rogel Cancer Center
University of Colorado, Denver
Oslo University Hospital
Oslo University Hospital
Northwestern University
City of Hope Medical Center
University of Michigan Rogel Cancer Center
National Taiwan University Hospital
Institut Bergonié
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center
University of Utah
M.D. Anderson Cancer Center
Institut Claudius Regaud
Sanford Health
University Health Network, Toronto
Instituto do Cancer do Estado de São Paulo
Columbia University
Fox Chase Cancer Center
Sarcoma Oncology Research Center, LLC
Memorial Sloan Kettering Cancer Center
Children's National Research Institute
North Eastern German Society of Gynaecological Oncology
Grupo Espanol de Investigacion en Sarcomas
Charles University, Czech Republic
Fred Hutchinson Cancer Center
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Washington University School of Medicine
Ohio State University Comprehensive Cancer Center
Massachusetts General Hospital
Grupo Espanol de Investigacion en Sarcomas
Masonic Cancer Center, University of Minnesota
University of Leeds
Fred Hutchinson Cancer Center
Institut Claudius Regaud
Brown University
OHSU Knight Cancer Institute
Brown University
Sheffield Teaching Hospitals NHS Foundation Trust
Maria Sklodowska-Curie National Research Institute of Oncology
Baylor College of Medicine
Baylor College of Medicine
UNICANCER
N.N. Petrov National Medical Research Center of Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
AC Camargo Cancer Center